Dynamic component (30%): Active contraction of myofibroblasts and hepatic stellate cells. Driven by imbalance between endogenous vasoconstrictors (endothelin-1, angiotensin II, norepinephrine, thromboxane A2) and vasodilators (reduced nitric oxide).
Increased Portal Blood Flow (Q):
Hyperdynamic circulation driven by splanchnic vasodilation.
Mediated by excessive release of endogenous vasodilators (nitric oxide, glucagon, vasoactive intestinal peptide).
Results in sodium/water retention, hypervolemia, and increased cardiac output.
Etiological Classification
Category
Specific Disorders
Prehepatic (Extrahepatic)
Portal vein thrombosis (most common extrahepatic cause in children), portal vein agenesis/atresia/stenosis, splenic vein thrombosis, arteriovenous fistula.
Budd-Chiari syndrome (hepatic vein or inferior vena cava obstruction/webs), right heart failure, constrictive pericarditis, Fontan circulation.
Clinical Manifestations
Primary Complications
Gastrointestinal Hemorrhage: Most common presentation. Hematemesis or melena originating from ruptured esophageal/gastric varices or portal hypertensive gastropathy.
Splenomegaly And Hypersplenism: Second most common finding. Causes sequestration of platelets and leukocytes, resulting in thrombocytopenia and leukopenia.
Ascites: Fluid accumulation when hydrostatic pressure exceeds osmotic pressure. Characterized by high serum-ascites albumin gradient (SAAG) ≥1.1 g/dL. Risk of spontaneous bacterial peritonitis.
Systemic And Extrahepatic Complications
System
Manifestations And Pathophysiology
Pulmonary
Hepatopulmonary Syndrome (HPS): Intrapulmonary microvascular dilations causing right-to-left shunting. Presents with hypoxemia, dyspnea, cyanosis, clubbing, orthodeoxia. Diagnosed via contrast-enhanced echocardiography or macroaggregated albumin scan.Portopulmonary Hypertension (PP-HTN): Pulmonary arterial hypertension (>25 mm Hg). Exertional dyspnea. Pulmonary arteriopathy with intimal fibrosis.
Renal
Hepatorenal Syndrome (HRS): Intense renal vasoconstriction secondary to severe splanchnic vasodilation. Presents as oliguria, low urine sodium, rising creatinine.
Neurological
Hepatic Encephalopathy: Especially in cirrhosis or prominent portosystemic shunting. Minimal hepatic encephalopathy compromises attention and psychomotor performance.
Biliary
Portal Hypertensive Biliopathy: Compression of biliary tree by cavernomatous collaterals in extrahepatic portal venous obstruction (EHPVO), causing strictures and cholestasis.
Diagnostic Evaluation
Non-Invasive Assessment
Laboratory: Thrombocytopenia (platelet count represents best non-invasive predictor of varices), altered coagulation (prothrombin time/INR), hypoalbuminemia, elevated transaminases/bilirubin (depending on underlying liver disease).
Abdominal Ultrasonography With Doppler: First-line modality. Defines vascular anatomy, portal vein patency, flow direction (hepatofugal flow suggests severe disease/bleeding risk), spleen size, ascites, and collateral vessels (cavernous transformation).
CT/MR Angiography: Delineates extrahepatic vascular anatomy, spontaneous shunts, and evaluates feasibility for surgical shunting.
Transient Elastography: Non-invasive surrogate for assessing liver/spleen stiffness to predict severe fibrosis and varices.
Invasive Assessment
Esophagogastroduodenoscopy (EGD): Gold standard for detecting and grading esophageal/gastric varices and portal hypertensive gastropathy. Predicts bleeding risk (red wale marks, large varices).
Hepatic Venous Pressure Gradient (HVPG): Measures difference between wedged (WHVP) and free (FHVP) hepatic venous pressures.
Normal: 1-5 mm Hg.
≥10 mm Hg: Varices formation.
≥12 mm Hg: Variceal bleeding risk.
Utility: Differentiates sinusoidal PH (elevated WHVP, high HVPG) from presinusoidal PH (normal WHVP, normal HVPG).
Management Protocol
Acute Variceal Hemorrhage
Medical emergency prioritizing hemodynamic stabilization and bleeding cessation.
Resuscitation: Intravenous crystalloids followed by packed red blood cells. Target hemoglobin 7-9 g/dL (avoid over-transfusion to prevent rebound portal pressure increase). Correct coagulopathy (vitamin K, fresh frozen plasma).
Pharmacotherapy:
Vasoactive agents to decrease splanchnic blood flow: Octreotide (1 mcg/kg bolus, followed by 1-5 mcg/kg/hr continuous infusion), Terlipressin, or Vasopressin.
Intravenous broad-spectrum antibiotics (cefotaxime/ceftriaxone) to prevent infectious complications.
Endoscopic Intervention: Endoscopic variceal ligation (EVL) preferred over sclerotherapy due to lower complication rates. Sclerotherapy utilized in infants too small for EVL banding device.
Rescue Therapy: Balloon tamponade (Sengstaken-Blakemore or Minnesota tube) for uncontrolled bleeding, serving as bridge to definitive intervention. Maximum inflation time 12 hours.
Prophylaxis Of Variceal Bleeding
Primary/Secondary Prophylaxis:
Non-selective beta-blockers (propranolol, nadolol) lower cardiac output and induce splanchnic vasoconstriction. Usage in young children debated due to reliance on heart rate for maintaining cardiac output.
Serial endoscopic band ligation or sclerotherapy until varices are completely obliterated.
Interventional radiology placement of stent between hepatic and portal vein. Bypasses liver resistance. Indicated for refractory variceal hemorrhage or intractable ascites. Used frequently as bridge to liver transplantation.
Meso-Rex Bypass
Superior mesenteric vein to left portal vein bypass. Procedure of choice for extrahepatic portal vein obstruction (EHPVO). Restores physiologic hepatopetal flow, alleviating hypersplenism, bleeding risk, and resolving neurocognitive/growth retardation.
Portosystemic Shunts
Distal splenorenal shunt (decompresses varices while maintaining hepatic flow; lower encephalopathy risk), mesocaval shunt, or portocaval shunt. Indicated in patients with preserved synthetic function failing endoscopic therapy.
Liver Transplantation
Definitive, curative therapy for portal hypertension secondary to progressive end-stage cirrhotic liver disease, severe hepatopulmonary syndrome, or failed medical/surgical management.